ANGPTL4 & Adipose RNA Update

A thin week on the primary beat — two correspondence letters debate ANGPTL4 as a stroke biomarker, while two independent studies use siRNA knockdown in human and porcine adipose-derived stem cells to probe fat biology, reinforcing the utility of RNA tools in adipose tissue.

ANGPTL4 emerges prominently as a therapeutic target in a landmark Circulation Research review of triglyceride-rich lipoprotein metabolism and cardiovascular risk in diabetes, while new work in adipocyte biology highlights PPARγ-mediated transcriptional programs and antiadipogenic peptide mechanisms with direct ANGPTL4 relevance.

Three new papers this week illuminate ANGPTL4's role in tumor microenvironments, adipose-driven metabolic dysfunction in heart failure, and as an early-life obesity biomarker; no new adipose RNA delivery papers appeared in the lookback window.

Intestinal ANGPTL4 emerges as a diet-and-microbiome integrator driving gut barrier dysfunction in early fatty liver disease, while new ionizable-lipid LNP platforms continue to expand the toolkit for tissue-selective RNA delivery beyond the liver.

This week's literature shows ANGPTL4 emerging as a multi-context tumor suppressor in head and neck cancer and a ferroptosis regulator in lung injury, while Mendelian randomization studies strengthen its causal standing in metabolic-cardiovascular disease; LNP delivery science advances on bone-marrow and lung-tumor fronts but adipose-selective RNA targeting remains an active gap.

A large LURIC cohort analysis ties CD-ANGPTL4 to heart failure incidence and mortality, an OPSCC study reframes ANGPTL4 as a tumor suppressor in head-and-neck cancer, and a Cardiovascular Diabetology review flags ANGPTL4 inhibition as a candidate combination therapy for diabetic vascular complications. Patent search is offline this week.

ANGPTL4 continues to generate broad clinical interest this week, with new mechanistic data in diabetic retinopathy, acute lung injury, and hepatocellular carcinoma; no new adipose-targeted RNA delivery papers appeared in the 7-day window.

Six new studies reinforce ANGPTL4 as a multi-tissue regulator with relevance to lipid metabolism, diabetic complications, and emerging therapeutic strategies; no adipose-targeted RNA delivery papers appeared in the past 7 days.

ANGPTL4 expanded its footprint in diabetic complications this week — strong mechanistic data implicating it in proliferative diabetic retinopathy and a new review on its role in diabetic nephropathy — alongside cancer angiogenesis, lung-injury cytoprotection, and head-and-neck SCC prognosis. No new adipose-targeted RNA delivery papers (siRNA/ASO/LNP/GalNAc) appeared in the lookback window.